Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma

Disclosures: Y.O. and A.Y. received research funding from Novartis.

Contributions: Y.O supervised the clinical trial, provided patient care, collected data, analyzed data, and wrote the paper. A.Y. designed the clinical trial, provided patient care, and wrote the paper. J.K. provided patient care, collected data, analyzed data and reviewed the paper. F.S., L.N., F.H., J.R., N.F., L.K., and J.W. provided patient care and edited paper. All authors approved the final version of the paper.